Activation of PPARβ/δ causes a psoriasis-like skin disease in vivo

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Romanowska, Malgorzata ^a   Reilly, Louise ^a   Palmer, Colin N A ^a   Gustafsson, Mattias C U ^b   Foerster, John ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD4 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 17; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ANIMAL; ARTICLE; BIOSYNTHESIS; DISEASE MODEL; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MOUSE; PHENOTYPE; PSORIASIS; SKIN DISEASE; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD31; ANTIGENS, CD4; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; MICE; MICE, TRANSGENIC; PHENOTYPE; PPAR-BETA; PSORIASIS; SKIN DISEASES; T-LYMPHOCYTES;

EID: 78649807501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009701     Document Type: Article

References (56)

1. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, et al. (2005) The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 52: 23-26.
2. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, et al. (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155: 729-736.
3. Wu Y, Mills D, Bala M (2008) Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 7: 373-377.
4. Poikolainen K, Karvonen J, Pukkala E (1999) Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 135: 1490-1493.
5. Finlay AY, Coles EC (1995) The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 132: 236-244.
6. Schmitt JM, Ford DE (2006) Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 213: 102-110.
7. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M (2006) Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298: 321-328.
8. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, et al. (2005) Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125: 61-67.
9. Barish GD, Narkar VA, Evans RM (2006) PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597.
10. Short B (2009) Time (and PPARbeta/delta) heals all wounds. J Cell Biol 184: 767.
11. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726-741.
12. Romanowska M, Yacoub N, Seidel H, Donandt S, Gerken H, et al. (2008) PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparinbinding EGF-like growth factor. J Invest Dermatol 128: 110-124.
13. Westergaard M, Henningsen J, Johansen C, Rasmussen S, Svendsen ML, et al. (2003) Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol 121: 1104-1117.
14. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, et al. (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15: 3263-3277.
15. Di-Poi N, Michalik L, Tan NS, Desvergne B, Wahli W (2003) The antiapoptotic role of PPARbeta contributes to efficient skin wound healing. J Steroid Biochem Mol Biol 85: 257-265.
16. Icre G, Wahli W, Michalik L (2006) Functions of the Peroxisome Proliferator-Activated Receptor (PPAR) alpha and beta in Skin Homeostasis, Epithelial Repair, and Morphogenesis. J Invest Dermatol 126 Suppl: 30-35.
17. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, et al. (2006) Activation of PPAR{beta}/{delta} Induces Endothelial Cell Proliferation and Angiogenesis. Arterioscler Thromb Vasc Biol.
18. van der Vleuten CJ, de Jong EM, van de Kerkhof PC (1996) Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res 288: 366-372.
19. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, et al. (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 102: 19057-19062.
20. Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339-1350.
21. Sabat R, Philipp S, Hoflich C, Kreutzer S, Wallace E, et al. (2007) Immunopathogenesis of psoriasis. Exp Dermatol 16: 779-798.
22. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, et al. (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41: 199-204.
23. Di-Poi N, Ng CY, Tan NS, Yang Z, Hemmings BA, et al. (2005) Epitheliummesenchyme interactions control the activity of peroxisome proliferatoractivated receptor beta/delta during hair follicle development. Mol Cell Biol 25: 1696-1712.
24. Campbell SJ, Carlotti F, Hall PA, Clark AJ, Wolf CR (1996) Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 109 (Pt 11): 2619-2625.
25. Robertson RW, Zhang L, Pasco DS, Fagan JB (1994) Aryl hydrocarbon-induced interactions at multiple DNA elements of diverse sequence-a multicomponent mechanism for activation of cytochrome P4501A1 (CYP1A1) gene transcription. Nucleic Acids Res 22: 1741-1749.
26. Rowe JM, Welsh C, Pena RN, Wolf CR, Brown K, et al. (2008) Illuminating role of CYP1A1 in skin function. J Invest Dermatol 128: 1866-1868.
27. Kaufman CK, Sinha S, Bolotin D, Fan J, Fuchs E (2002) Dissection of a complex enhancer element: maintenance of keratinocyte specificity but loss of differentiation specificity. Mol Cell Biol 22: 4293-4308.
28. Michalik L, Wahli W (2007) Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 1771: 991-998.
29. Rosenfield RL, Kentsis A, Deplewski D, Ciletti N (1999) Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 112: 226-232.
30. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, et al. (2006) Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 126: 2002-2009.
31. Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, et al. (2006) Antiinflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med 12: 330-334.
32. Chiaro CR, Morales JL, Prabhu KS, Perdew GH (2008) Leukotriene A4 metabolites are endogenous ligands for the Ah receptor. Biochemistry 47: 8445-8455.
33. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR (2008) Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 49: 499-509.
34. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, et al. (2005) Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11: 43-49.
35. Koegel H, von Tobel L, Schafer M, Alberti S, Kremmer E, et al. (2009) Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice. J Clin Invest 119: 899-910.
36. Murray PJ (2006) STAT3-mediated anti-inflammatory signalling. Biochem Soc Trans 34: 1028-1031.
37. Azfar RS, Gelfand JM (2008) Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 20: 416-422.
38. Sun L, Ke Y, Zhu CY, Tang N, Tian DK, et al. (2008) Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, reexploring secondary organ complications of spontaneously hypertensive rats. Chin Med J (Engl) 121: 2305-2311.
39. Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, Bonkowski MS, Panici JA, et al. (2005) Caloric restriction results in decreased expression of peroxisome proliferator-activated receptor superfamily in muscle of normal and long-lived growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 60: 1238-1245.
40. Sutherland JP, McKinley B, Eckel RH (2004) The metabolic syndrome and inflammation. Metab Syndr Relat Disord 2: 82-104.
41. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G (2008) Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 88: 1242-1247.
42. Barish GD, Atkins AR, Downes M, Olson P, Chong LW, et al. (2008) PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci U S A 105: 4271-4276.
43. Hall JM, McDonnell DP (2007) The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. Mol Endocrinol 21: 1756-1768.
44. Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, et al. (2007) Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 179: 1423-1426.
45. Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, et al. (2006) The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 8: R80.
46. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, et al. (2007) Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 204: 2603-2614.
47. Chong HC, Tan MJ, Philippe V, Tan SH, Tan CK, et al. (2009) Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing. J Cell Biol 184: 817-831.
48. Debets R, Hegmans JP, Croughs P, Troost RJ, Prins JB, et al. (1997) The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 158: 2955-2963.
49. Kang K, Hatano B, Lee CH (2007) PPAR delta agonists and metabolic diseases. Curr Atheroscler Rep 9: 72-77.
50. Liu L, Gao Y, Qiu H, Miller WT, Poli V, et al. (2006) Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 25: 4904-4912.
51. El Kasmi KC, Holst J, Coffre M, Mielke L, de Pauw A, et al. (2006) General nature of the STAT3-activated anti-inflammatory response. J Immunol 177: 7880-7888.
52. Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, et al. (2004) Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 122: 971-983.
53. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, et al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154: 799-814.
54. de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, et al. (2009) Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 41: 211-215.
55. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, et al. (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14: 5759-5768.
56. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, et al. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408.